11.64
0.87%
+0.10
Iovance Biotherapeutics Inc stock is currently priced at $11.64, with a 24-hour trading volume of 2.48M.
It has seen a +0.87% increased in the last 24 hours and a -17.15% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.45 pivot point. If it approaches the $11.74 resistance level, significant changes may occur.
Previous Close:
$11.54
Open:
$11.6
24h Volume:
2.48M
Market Cap:
$3.25B
Revenue:
-
Net Income/Loss:
$-444.04M
P/E Ratio:
-5.1964
EPS:
-2.24
Net Cash Flow:
$-384.11M
1W Performance:
+2.92%
1M Performance:
-17.15%
6M Performance:
+214.59%
1Y Performance:
+112.80%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
650-260-7120
Address
999 Skyway Road, Suite 150, San Carlos
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-20-23 | Initiated | Goldman | Buy |
Sep-18-23 | Reiterated | Barclays | Overweight |
May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
Jan-28-22 | Upgrade | Stifel | Hold → Buy |
Dec-07-21 | Resumed | Cowen | Outperform |
Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
May-19-21 | Downgrade | Stifel | Buy → Hold |
May-03-21 | Initiated | Truist | Buy |
Apr-16-21 | Initiated | Goldman | Buy |
Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-22-20 | Initiated | Mizuho | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
Feb-26-20 | Reiterated | Oppenheimer | Outperform |
Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
Oct-01-19 | Initiated | Stifel | Buy |
Apr-29-19 | Initiated | Piper Jaffray | Overweight |
Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-07-19 | Initiated | Robert W. Baird | Outperform |
Dec-31-18 | Resumed | B. Riley FBR | Buy |
Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
3 Millionaire-Maker Biotech Stocks
The Motley Fool
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
GlobeNewswire Inc.
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Is Iovance Biotherapeutics Stock a Buy Now?
The Motley Fool
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Zacks Investment Research
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Iovance Biotherapeutics Inc (IOVA) Net Income 2024
IOVA net income (TTM) was -$444.04 million for the quarter ending December 31, 2023, a -12.16% decrease year-over-year.
Iovance Biotherapeutics Inc (IOVA) Cash Flow 2024
IOVA recorded a free cash flow (TTM) of -$384.11 million for the quarter ending December 31, 2023, a -22.65% decrease year-over-year.
Iovance Biotherapeutics Inc (IOVA) Earnings per Share 2024
IOVA earnings per share (TTM) was -$1.88 for the quarter ending December 31, 2023, a +24.19% growth year-over-year.
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Cap:
|
Volume (24h):